A Double-blind, Placebo-controlled, Multicenter, Prospective, Randomized Study of Beraprost Sodium Treatment for Cats with Chronic Kidney Disease

Overview

Journal J Vet Intern Med

Specialties General Medicine
Veterinary Medicine

Date 2017 Nov 14

PMID 29131397

Citations 8

Authors

M Takenaka

A Iio

R Sato

T Sakamoto

H Kurumatani

Affiliations

Soon will be listed here.

Abstract

Background: Chronic kidney disease (CKD) is a common progressive and irreversible disease in cats. The efficacy and safety of beraprost sodium (BPS) in cats with CKD have not been evaluated.

Hypothesis/objectives: To evaluate the efficacy and safety of BPS in the treatment of cats with CKD, as compared to placebo.

Animals: Seventy-four client-owned cats with naturally occurring CKD.

Methods: Double-blind, placebo-controlled, multicenter, prospective, randomized trial. The cats received BPS (55 μg/cat) or a placebo PO q12 h for 180 days. The primary endpoint was prospectively defined as a change in the serum creatinine (sCr), serum phosphorus-to-calcium ratio or urine specific gravity (USG).

Results: The sCr increased significantly (P = 0.0030) in the placebo group (mean ± SD: 2.8 ± 0.7 to 3.2 ± 1.3 mg/dL) but not in the BPS group (2.4 ± 0.7 to 2.5 ± 0.7 mg/dL). The difference between the groups at day 180 was significant (0.8 mg/dL, 95% CI: 0.2 to 1.3 mg/dL, P = 0.0071). The serum phosphorus-to-calcium ratio was significantly (P = 0.0037) increased in the placebo group (0.46 ± 0.10 to 0.52 ± 0.21 mg/dL) but not in the BPS group (0.50 ± 0.08 to 0.51 ± 0.11 mg/dL). There was no significant change in the USG in either group. An adverse event judged as being treatment-related included vomiting that occurred in 1 case in the placebo group. No clinically relevant change was observed in the CBC and other blood chemistry tests.

Conclusions And Clinical Importance: Beraprost sodium treatment was well tolerated and safe in cats with CKD. BPS inhibited the reduction in renal filtration function as measured by sCr increase.

Citing Articles

Effects of Beraprost with or without NOS Inhibition on Plasma Aldosterone and Hemodynamics in Healthy Cats.

Matsuura T, Yoshimura A, Fukushima R Vet Sci. 2024; 11(4).

PMID: 38668422 PMC: 11054574. DOI: 10.3390/vetsci11040155.

Beraprost and Overall Survival in Cats with Chronic Kidney Disease.

Ito H, Matsuura T, Sano T Vet Sci. 2023; 10(7).

PMID: 37505864 PMC: 10384921. DOI: 10.3390/vetsci10070459.

Beraprost Sodium for Pulmonary Hypertension in Dogs: Effect on Hemodynamics and Cardiac Function.

Suzuki R, Yuchi Y, Saito T, Yasumura Y, Teshima T, Matsumoto H Animals (Basel). 2022; 12(16).

PMID: 36009668 PMC: 9405226. DOI: 10.3390/ani12162078.

Evaluation of Renal Blood Flow in Dogs during Short-Term Human-Dose Epoprostenol Administration Using Pulsed Doppler and Contrast-Enhanced Ultrasonography.

Hanazono K, Itami T, Hayasaka I, Miyoshi K, Hori A, Kato K Animals (Basel). 2022; 12(9).

PMID: 35565601 PMC: 9103000. DOI: 10.3390/ani12091175.

Investigation of Beraprost Sodium on Cardiac Function and Hemodynamics in Canine Models of Chronic Pulmonary Hypertension.

Suzuki R, Yuchi Y, Saito T, Teshima T, Matsumoto H, Koyama H Front Vet Sci. 2022; 9:876178.

PMID: 35498754 PMC: 9048895. DOI: 10.3389/fvets.2022.876178.

References

Lawson J, Elliott J, Wheeler-Jones C, Syme H, Jepson R . Renal fibrosis in feline chronic kidney disease: known mediators and mechanisms of injury. Vet J. 2014; 203(1):18-26. DOI: 10.1016/j.tvjl.2014.10.009. View

Lievre M, Morand S, Besse B, Fiessinger J, Boissel J . Oral Beraprost sodium, a prostaglandin I(2) analogue, for intermittent claudication: a double-blind, randomized, multicenter controlled trial. Beraprost et Claudication Intermittente (BERCI) Research Group. Circulation. 2000; 102(4):426-31. DOI: 10.1161/01.cir.102.4.426. View

Fujita T, Fuke Y, Satomura A, Hidaka M, Ohsawa I, Endo M . PGl2 analogue mitigates the progression rate of renal dysfunction improving renal blood flow without glomerular hyperfiltration in patients with chronic renal insufficiency. Prostaglandins Leukot Essent Fatty Acids. 2001; 65(4):223-7. DOI: 10.1054/plef.2001.0315. View

Sent U, Gossl R, Elliott J, Syme H, Zimmering T . Comparison of Efficacy of Long-term Oral Treatment with Telmisartan and Benazepril in Cats with Chronic Kidney Disease. J Vet Intern Med. 2015; 29(6):1479-87. PMC: 4895689. DOI: 10.1111/jvim.13639. View

Yamaguchi S, Inada C, Tamura M, Sato N, Yamada M, Itaba S . Beraprost sodium improves survival rates in anti-glomerular basement membrane glomerulonephritis and 5/6 nephrectomized chronic kidney disease rats. Eur J Pharmacol. 2013; 714(1-3):325-31. DOI: 10.1016/j.ejphar.2013.07.032. View

Risdon R, Sloper J, DE WARDENER H . Relationship between renal function and histological changes found in renal-biopsy specimens from patients with persistent glomerular nephritis. Lancet. 1968; 2(7564):363-6. DOI: 10.1016/s0140-6736(68)90589-8. View

Yokoyama C, Yabuki T, Shimonishi M, Wada M, Hatae T, Ohkawara S . Prostacyclin-deficient mice develop ischemic renal disorders, including nephrosclerosis and renal infarction. Circulation. 2002; 106(18):2397-403. DOI: 10.1161/01.cir.0000034733.93020.bc. View

Chakrabarti S, Syme H, Elliott J . Clinicopathological variables predicting progression of azotemia in cats with chronic kidney disease. J Vet Intern Med. 2012; 26(2):275-81. DOI: 10.1111/j.1939-1676.2011.00874.x. View

Yabuki A, Mitani S, Fujiki M, Misumi K, Endo Y, Miyoshi N . Comparative study of chronic kidney disease in dogs and cats: induction of myofibroblasts. Res Vet Sci. 2009; 88(2):294-9. DOI: 10.1016/j.rvsc.2009.09.003. View

10.

Guan J, Long L, Chen Y, Yin Y, Li L, Zhang C . Effects of beraprost sodium on renal function and inflammatory factors of rats with diabetic nephropathy. Genet Mol Res. 2014; 13(2):4154-8. DOI: 10.4238/2014.June.9.1. View

11.

Fine L, Orphanides C, Norman J . Progressive renal disease: the chronic hypoxia hypothesis. Kidney Int Suppl. 1998; 65:S74-8. View

12.

Chakrabarti S, Syme H, Brown C, Elliott J . Histomorphometry of feline chronic kidney disease and correlation with markers of renal dysfunction. Vet Pathol. 2012; 50(1):147-55. DOI: 10.1177/0300985812453176. View

13.

Syme H, Markwell P, Pfeiffer D, Elliott J . Survival of cats with naturally occurring chronic renal failure is related to severity of proteinuria. J Vet Intern Med. 2006; 20(3):528-35. DOI: 10.1892/0891-6640(2006)20[528:socwno]2.0.co;2. View

14.

Nagaya N, Uematsu M, Okano Y, Satoh T, Kyotani S, Sakamaki F . Effect of orally active prostacyclin analogue on survival of outpatients with primary pulmonary hypertension. J Am Coll Cardiol. 1999; 34(4):1188-92. DOI: 10.1016/s0735-1097(99)00312-5. View

15.

Goto Y, Yamaguchi S, Tamura M, Mochizuki H, Kurumatani H, Okano K . A prostacyclin analog prevents the regression of renal microvascular network by inhibiting mitochondria-dependent apoptosis in the kidney of rat progressive glomerulonephritis. Prostaglandins Other Lipid Mediat. 2014; 112:16-26. DOI: 10.1016/j.prostaglandins.2014.06.001. View

16.

Nath K . Tubulointerstitial changes as a major determinant in the progression of renal damage. Am J Kidney Dis. 1992; 20(1):1-17. DOI: 10.1016/s0272-6386(12)80312-x. View

17.

Geddes R, Elliott J, Syme H . Relationship between Plasma Fibroblast Growth Factor-23 Concentration and Survival Time in Cats with Chronic Kidney Disease. J Vet Intern Med. 2015; 29(6):1494-501. PMC: 4895675. DOI: 10.1111/jvim.13625. View

18.

Sparkes A, Caney S, Chalhoub S, Elliott J, Finch N, Gajanayake I . ISFM Consensus Guidelines on the Diagnosis and Management of Feline Chronic Kidney Disease. J Feline Med Surg. 2016; 18(3):219-39. PMC: 11148907. DOI: 10.1177/1098612X16631234. View

19.

King J, Tasker S, Gunn-Moore D, Strehlau G . Prognostic factors in cats with chronic kidney disease. J Vet Intern Med. 2007; 21(5):906-16. View

20.

Polzin D . Evidence-based step-wise approach to managing chronic kidney disease in dogs and cats. J Vet Emerg Crit Care (San Antonio). 2013; 23(2):205-15. DOI: 10.1111/vec.12034. View